MTE #12: Beyond Fibrosis Staging—Integrating Hemodynamics and Noninvasive Testing for Predicting Portal Hypertension Decompensation, Recompensation, and Therapeutic Response (Ticketed)

Risk stratification in chronic liver disease is evolving from static fibrosis staging toward dynamic prediction of cirrhosis progression, portal hypertension, and clinical decompensation. Learn from topic experts who examine how established and emerging noninvasive tools—using a physiology-driven approach—can more accurately capture the determinants of disease progression. Disscussants integrate conventional serum and elastography-based noninvasive tests with emerging hemodynamic imaging, including magnetic resonance flow models (eg, magnetic resonance phase contrast vastly undersampled imaging with projection reconstruction; MR PC-VIPR) to highlight their complementary roles in assessment of portal hypertension and decompensation risk. Through expert commentary and case-based discussion, participants examine how combining structural and functional biomarkers can improve prediction of first decompensation, adverse clinical outcomes, and therapeutic responses. Faculty emphasize practical application, limitations of current evidence, and future directions for incorporating advanced noninvasive tools into longitudinal patient management and accelerating outcome-driven clinical trials in cirrhosis.